Literature DB >> 17552064

Outcome evaluations in gout.

H Ralph Schumacher1, William Taylor, Nancy Joseph-Ridge, Fernando Perez-Ruiz, Lan X Chen, Naomi Schlesinger, Dinesh Khanna, Daniel E Furst, Michael A Becker, Nicola Dalbeth, N Lawrence Edwards.   

Abstract

Methods to measure outcomes in gout still require consensus and validation. This Special Interest Group was assembled to identify domains of interest and is now evaluating a series of outcomes for features of acute gouty arthritis and chronic gout. To accomplish this, working groups have been formed and domains identified. Delphi methodology has been used to address gouty flares as an outcome of greatest interest. Studies addressing other outcome measures were reported at the OMERACT 8 meeting and validation has begun on some outcomes. There has been progress on developing a definition of a flare, and validating reproducibility of some chronic gout outcome measures in some domains, such as tophus size and patient perceptions. Use of these outcomes as well as a health-related quality of life measure are being studied in clinical trials. Pain on a Likert scale appears to be a valid outcome in acute gout. Final validation of these outcomes has not yet been achieved. In summary, the unique problems of evaluating outcomes in gout are finally being addressed. While no measures are available for use yet, an agenda has been developed.

Entities:  

Mesh:

Year:  2007        PMID: 17552064

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

1.  As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Authors:  A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich
Journal:  Rheumatol Int       Date:  2013-09-12       Impact factor: 2.631

Review 2.  Outcome measures in acute gout: a systematic literature review.

Authors:  Nicola Dalbeth; Cathy S Zhong; Rebecca Grainger; Dinesh Khanna; Puja P Khanna; Jasvinder A Singh; Fiona M McQueen; William J Taylor
Journal:  J Rheumatol       Date:  2013-12-15       Impact factor: 4.666

3.  Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials.

Authors:  Jasvinder A Singh; Shuo Yang; Vibeke Strand; Lee Simon; Anna Forsythe; Steve Hamburger; Lang Chen
Journal:  Ann Rheum Dis       Date:  2011-07       Impact factor: 19.103

4.  Disease modification in gout: a qualitative study of gout expert rheumatologists.

Authors:  Jasvinder A Singh
Journal:  Rheumatol Adv Pract       Date:  2022-01-03

5.  Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.

Authors:  Janitzia Vazquez-Mellado; Ingris Peláez-Ballestas; Rubén Burgos-Vargas; Everardo Alvarez-Hernández; Sergio García-Méndez; Virginia Pascual-Ramos; Marina Rull-Gabayet
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

6.  Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease.

Authors:  A Kirstin Bacani; Cynthia H McCollough; Katrina N Glazebrook; Jeffrey R Bond; Clement J Michet; Jeffrey Milks; Nisha J Manek
Journal:  Rheumatol Int       Date:  2009-12-17       Impact factor: 2.631

Review 7.  Gout. Novel therapies for treatment of gout and hyperuricemia.

Authors:  Robert Terkeltaub
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

Review 8.  Imaging of gout: findings and utility.

Authors:  Fernando Perez-Ruiz; Nicola Dalbeth; Aranzazu Urresola; Eugenio de Miguel; Naomi Schlesinger
Journal:  Arthritis Res Ther       Date:  2009-06-17       Impact factor: 5.156

9.  Development of a multivariable improvement measure for gout.

Authors:  Naomi Schlesinger; N Lawrence Edwards; Anthony E Yeo; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2020-06-29       Impact factor: 5.156

10.  One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.

Authors:  Till Uhlig; Lars F Karoliussen; Joe Sexton; Tore K Kvien; Espen A Haavardsholm; Fernando Perez-Ruiz; Hilde Berner Hammer
Journal:  Arthritis Res Ther       Date:  2022-04-20       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.